14 June 2017

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will hold its Annual General Meeting ("AGM") in London later today.

Futura's Chairman, John Clarke, will deliver the following statement at the meeting:

"The development and commercialisation of our product pipeline continues apace and we have made good progress in the year to date especially across our sexual health products: MED2002 and CSD500.

"As announced at the end of last month, we have received constructive feedback from US and UK regulatory authorities on the clinical and regulatory pathway for MED2002, our topical gel for erectile dysfunction. As a result of this feedback we expect our Phase III programme of MED2002 to proceed as planned, with the first patient dosed in Q4 this year. We continue to receive significant commercial interest in MED2002 from potential licensing partners and negotiations are ongoing.

"On CSD500, our novel erectogenic condom, we are currently assisting all our EU licensing partners wherever required with their launch plans in a number of countries. In addition, we have in production two manufacturing orders from our licensing partner for the Middle East and North Africa, following its launch of CSD500 in Saudi Arabia earlier this year.

"We continue in discussions on the out-licensing of our two pain relief products, TIB200 and TPR100, with potential licensing partners. We look forward to providing an update on these discussions, and on other corporate developments, in due course.

"Futura continues to benefit from a strong financial position and we look forward to the year ahead with confidence."

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong / Thomas Smale
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan Communications Limited
Mark Court / Sophie Cowles /
Stephanie Watson
Tel: +44 (0) 20 7466 5000

 

Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com